San Francisco, CA USA (UroToday.com) Dr. Pooja Ghatalia and her associates at Fox Chase Cancer Center presented their survival data on small cell Ca of the bladder (SCBC) in today’s poster session of the 2016 GU ASCO conference.
The investigators performed a retrospective analysis of 38 patients with pure or mixed SCBC/urothelial histology from 1995-2015. Mean age at diagnosis was 68.2 years, all patients were Caucasian, and 26 (69.4%) were smokers. Radical cystectomy was performed in 26 patients (69.4%), 3 patients (7.9%) received surgery and adjuvant RT, and 5 (13.2%) received RT monotherapy. All patients received chemotherapy: 32 patients (84.2%) received neoadjuvant, 3 (7.9%) received adjuvant, and 2 (5.3%) received both.
16 patients progressed with a median time to progression of 7.7 months. Median OS was 397 days (309-633) while median PFS was 332 days (427-608). No temporal trends in OS or PFS were identified.
The authors concluded that there have been no improvements in the outcomes of SCBC patients over the past decade. Larger cohorts with further analysis may provide more insight into the comparative effectiveness of varying treatment.
Presented By:
Dr. Pooja Ghatalia, MD
Fox Chase Cancer Center, Philadelphia, PA
Reported By:
Nikhil Waingankar, MD at the 2016 Genitourinary Cancers Symposium - January 7 - 9, 2016 – San Francisco, CA
Fox Chase Cancer Center, Philadelphia, PA